Clinical Trial Update: Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of PA1010 in HBV Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update evaluating safety, tolerability, PK and PD of PA1010 in chronic HBV infection has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hbv Infection
• Hepatitis B

Drugs mentioned

• PA1010

Snippet

Sponsor: Zhejiang Palo Alto Pharmaceuticals, Inc. | Conditions: Chronic HBV Infection | Phase 1, Phase 2 | Status: COMPLETED